We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App

Artificial Intelligence Helps Identify T-cell Targets for Development of SARS-CoV-2 Vaccine

By HospiMedica International staff writers
Posted on 10 Jul 2020
Print article
A neoantigen prediction platform that employs state-of-the-art bioinformatics and artificial intelligence (AI) to identify an optimal set of neoantigens as targets for cancer vaccines or adoptive cell therapies is being used for the development of a SARS-CoV-2 vaccine.

The neoantigen prediction platform called ArdImmune Vax has been developed by Ardigen (Kraków, Poland) and is very well suited for the design of vaccines for infectious diseases. The core of the platform is a proprietary algorithm capable of predicting neoantigens' probability to elicit an immune response.

ArdImmune has now entered into a research collaboration with COVID-19 Vaccine Corporation (CVC Auckland; New Zealand) aimed at the development of SARS-CoV-2 vaccine. The joint research enables CVC to benefit from Ardigen's vaccine design technology by selecting which viral epitopes are the most suitable to boost cellular immune response. Complementing humoral and cellular response in the vaccine design is expected to result in two strong lines of defense against the coronavirus. This approach is likely to be more effective than vaccines designed to create antibodies alone.

"We are thrilled to help global efforts to mitigate COVID-19 applying our breakthrough technology powered by artificial intelligence, reducing the vaccine design phase to a few weeks," said Janusz Homa, CEO of Ardigen.

"CVC is excited to be working with Ardigen who are at the forefront of T-cell epitope design. The collaboration gives us the best chance of our product inducing an effective T-cell response against SARS-Cov-2," said Robert Feldman, CEO and Co-founder of CVC.

Related Links:
COVID-19 Vaccine Corporation

Print article



view channel

Siemens to Acquire Varian Medical to Create Comprehensive Cancer Portfolio

Siemens Healthineers (Erlangen, Germany) has entered into an agreement to acquire Varian Medical Systems, Inc. (Palo Alto, CA, USA) that will lead to the creation of a global leader in healthcare with... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.